{"public_id":"co_9bde39b4d05974eb4e42400d59e05200","status":"active","merged_into_public_id":null,"resolved_public_id":"co_9bde39b4d05974eb4e42400d59e05200","name":"mild/moderate renal impairment","description":"Reduced kidney function subgroup analyzed separately for efficacy outcomes.","aliases":["renal impairment"],"types":["patient subgroup"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":6351267,"title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","citation_count":519,"url":"https://sah.borca.ai/papers/6351267"}],"claims":[{"public_id":"cl_2ec0e0c278687abf79d08773ee118252","text":"Among subjects with mild or moderate renal impairment, both febuxostat doses were more efficacious than allopurinol for reaching serum urate <6.0 mg/dL.","corpus_id":6351267,"url":"https://sah.borca.ai/claims/cl_2ec0e0c278687abf79d08773ee118252"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_9bde39b4d05974eb4e42400d59e05200","url":"https://sah.borca.ai/concepts/co_9bde39b4d05974eb4e42400d59e05200"}